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ABSTRACT 39	  
Neuronal ceroid lipofuscinoses (NCL) are a group of incurable lysosomal storage 40	  
disorders characterized by neurodegeneration and accumulation of lipopigments 41	  
mainly within the neurons. We studied two littermate Chihuahua dogs presenting with 42	  
progressive signs of blindness, ataxia, pacing and cognitive impairment from the age 43	  
of one year old. Due to worsening of clinical signs, both dogs were euthanized at 44	  
around two years of age. Post-mortem examination revealed marked accumulation of 45	  
autofluorescent intracellular inclusions within the brain, characteristic of NCL. Whole 46	  
genome sequencing was performed on one of the affected dogs. Following sequence 47	  
alignment and variant calling against the canine reference genome, variants were 48	  
identified in the coding region or splicing regions of four previously known NCL 49	  
genes (CLN6, ARSG, CLN2=TPP1 and CLN7=MFSD8). Subsequent segregation 50	  
analysis within the family (two affected dogs, both parents and three relatives) 51	  
identified MFSD8:p.Phe282Leufs13* as the causal mutation, which had previously 52	  
been identified in one Chinese crested dog with no available ancestries. Due to the 53	  
similarities of the clinical signs and histopathological changes with the human form of 54	  
the disease, we propose that the Chihuahua dog could be a good animal model of 55	  
CLN7 disease. 56	  
 57	  58	  
SIGNIFICANCE STATEMENT  59	  
NCL are a group of incurable lysosomal storage disorders unified by similar 60	  
histopathological changes. Although mutations in 13 genes coding for functionally 61	  
distinct proteins have been identified, the pathophysiology of these diseases is still  62	  
poorly understood. Naturally occurring large animal models have had an invaluable 63	  
contribution to better understand the pathophysiology and therapeutic options of some 64	  
forms of NCL. CLN7 is a poorly characterized form, and this could be due to a lack 65	  
of animal models that closely reproduce the human phenotype. We identified 66	  
Chihuahua dogs with a genetic mutation causing CLN7 disease, which could 67	  
represent an excellent animal model. 68	  
 69	  
INTRODUCTION 70	  
Neuronal Ceroid Lipofuscinoses (NCL) are a heterogeneous group of inherited 71	  
lysosomal storage disorders characterized by neurodegeneration and accumulation of 72	  
autofluorescent lipopigments mainly in neurons. In human patients, they represent the 73	  
most prevalent hereditary neurovisceral storage disorder with an incidence of 1.3 to 7 74	  
for every 100,000 live births, depending on the country (Mole and Williams, 2001 75	  
[Updated 2013]). Symptoms usually include blindness, motor and cognitive decline, 76	  
seizures and premature death. The disease was originally classified on the basis of age 77	  
of onset and clinical signs into congenital, infantile, late-infantile, juvenile and adult 78	  
forms, with many possible variants (Mole and Williams, 2001 [Updated 2013]; 79	  
Shacka, 2012). More than 400 different mutations in thirteen genes have been 80	  
identified in human patients, and three genes have recently been suggested as – 81	  
unproven – candidate genes (Di Fruscio et al., 2015). Despite coding for functionally 82	  
distinct proteins   ̶  some soluble and some transmembrane proteins  ̶  mutations of 83	  
these genes all induce accumulation of autofluorescence storage material (Shacka, 84	  
2012). Mutations in different genes can result in similar phenotypes, whereas different 85	  
mutations in the same gene can lead to a very different disease course. This rendered 86	  
the original classification based on age of onset of limited value. The current 87	  
characterization of NCL forms is now based on the causative mutation (Mole and 88	  
Williams, 2001 [Updated 2013]).  89	  
 90	  
Numerous animal models of NCLs have been described and have been invaluable in 91	  
contributing to the current understanding of this devastating condition. However, 92	  
despite extensive research, the disease mechanisms are still not fully understood and 93	  
animal models provide the opportunity to further understand the pathophysiology and 94	  
assess new therapeutic strategies for each different form. In veterinary medicine, NCL 95	  
has been described in various species including the sheep, cow, goat, horse, ferret, cat 96	  
and dog (Jolly and Palmer, 1995; Anderson et al., 2013). In dogs, the causative 97	  
mutation has been found in many breeds, including the American Bulldog (CLN10) 98	  
(Awano et al., 2006), Border Collie (CLN5) (Melville et al., 2005), English Setter 99	  
(CLN8) (Katz et al., 2005a), Dachshund (CLN1 and CLN2) (Awano et al., 2006; 100	  
Sanders et al., 2010), Tibetan Terrier (ATP13A2 = CLN12) (Farias et al., 2011; 101	  
Wohlke et al., 2011), Australian Shepherd (CLN6) (Katz et al., 2011), Golden 102	  
Retriever (CLN5) (Gilliam et al., 2015), Australian Shepherd mix (CLN8) (Guo et al., 103	  
2014) and more recently strongly suspected in a single Chinese Crested dog (MFSD8 104	  
= CLN7) (Guo et al., 2015). Mutation in ARSG (Arylsulfatase G) has also been 105	  
identified in the American Staffordshire Bull Terrier suffering from a lysosomal 106	  
storage disorder initially classified as NCL (Abitbol et al., 2010); however, more 107	  
recent reports suggest that ARSG-deficiency should be referred as a 108	  
mucopolysaccharidosis (more precisely MPS IIIE) (Kowalewski et al., 2012; 109	  
Kowalewski et al., 2015). Multiple sporadic reports of Chihuahua dogs affected by 110	  
NCL exist (Rac and Giesecke, 1975; Kuwamura et al., 2003; Nakamoto et al., 2011), 111	  
but, to date, the causative mutation has not been identified.  112	  
We present here a family of Chihuahua dogs with a progressive neurological disease 113	  
confirmed to be a form of NCL after histopathologic and ultrastructural examinations. 114	  
After generating a whole genome sequence using DNA from one of the affected dogs, 115	  
a mutation in MFSD8 (CLN7) gene was identified and this was confirmed by 116	  
segregation analysis in the related dogs. The Chihuahua dog could represent a new 117	  
animal model for CLN7 disease. 118	  
 119	  
MATERIAL AND METHODS 120	  
1. Patient cohort – Clinical investigations 121	  
Two littermate Chihuahua dogs (one male and one female) were presented to the 122	  
Small Animal Hospital, University of Glasgow, for investigation of progressive 123	  
neurological signs. Following clinical examination and routine complete blood count 124	  
and biochemistry, they underwent magnetic resonance imaging (MRI) of the brain 125	  
under general anesthesia. MR images were acquired using a 1.5 T (64 MHz) system 126	  
(Magnetom Essenza, Siemens, Camberley, UK). T2-weighted, Fluid-attenuated 127	  
inversion recovery, T2*-weighted, and T1-weighted images prior and after contrast 128	  
were acquired in sagittal, transverse and dorsal planes. Routine cerebrospinal fluid 129	  
analysis including total nucleated cell count, cytology and protein measurement was 130	  
performed in the two affected cases and urinary organic acid screening by mass 131	  
spectrometry was performed in the male dog. 	  132	  
	  133	  
2. Histopathology and electron microscopy	  134	  
The male dog was euthanized at 1 year 11 months of age and underwent a full post-135	  
mortem examination. Representative samples from the cerebrum and cerebellum were 136	  
fixed in 2.5 % glutaraldehyde for electron microscopy (EM) analysis and other 137	  
samples from the cerebrum and cerebellum were embedded in Tissue-Tek O.C.T 138	  
(Sakura) and snapped frozen in isopentane chilled in liquid nitrogen before being 139	  
stored at -80 °C for fluorescence microscopy. The rest of the brain, the eyes, and 140	  
samples from skin, liver, kidney, adrenal, spleen, heart, duodenum and pancreas were 141	  
fixed in 10 % buffered formalin. Slices of the formalin-fixed brain were then 142	  
embedded in paraffin, before staining with hematoxilin and eosin (H&E), PAS, Sudan 143	  
blue and Luxol fast blue. Samples for fluorescence microscopy were analysed as 144	  
previously described (Katz et al., 2005b). Immunostaining was performed using 145	  
antibodies directed against glial fibrillary acid protein (GFAP) and lysosomal-146	  
associated membrane protein 1 (LAMP-1) (see Table I for details of antibodies used).  147	  
 148	  
3. Family analysis – Ethical statement 149	  
The breeder of the affected dogs was contacted and agreed to provide DNA samples 150	  
in the form of cheek swabs from the parents of the dogs and from related family 151	  
members (Fig. 1). EDTA blood samples were available from the two affected dogs.  152	  
Approval from the local ethical committee (University of Glasgow, School of 153	  
Veterinary Medicine) was granted (Form Ref. 12a/14) for this study.  154	  
 155	  
4. Molecular analysis 156	  
DNA was extracted from the blood of the two affected animals using a DNeasy Blood 157	  
and Tissue kit (Qiagen, Crawley, UK) and from the cheek swabs using a Gentra 158	  
Puregene Buccal Cell Kit (Qiagen, Crawley, UK).  159	  
Whole-genome sequencing was performed on the affected female dog using 160	  
Illumina’s TruSeq PCR free protocol according to the manufacturer’s instructions 161	  
combined with Illumina’s Hiseq2000 on paired-end 100bp reads. Sequence alignment 162	  
and variant calling were performed against the dog genome reference CanFam3.1 163	  
using bwa (Li and Durbin, 2009) and the Genome Analysis Toolkit respectively 164	  
(McKenna et al., 2010; DePristo et al., 2011), largely following the Best Practices v3, 165	  
with hard filters for variant recalibration. In short, this consisted of duplicate read 166	  
marking, realignment around indels, base quality score recalibration, variant 167	  
identification using the HaplotypeCaller tool. High quality variants were annotated 168	  
using snpEff (Cingolani et al., 2012) against the dog reference CanFam3.1.75. 169	  
The data were initially analyzed for known NCL genes. Given the apparent autosomal 170	  
recessive mode of transmission of the disease in the family, homozygous variants in 171	  
the coding exons or splicing regions of previously described NCL genes were 172	  
prioritized. Variants were identified in CLN6, ARSG, TPP1 and MFSD8 genes. 173	  
Segregation analysis for these candidates was performed by Sanger sequencing. 174	  
Following PCR amplification (see Table II for mutation location and primers used), 175	  
the PCR products were purified using ExoSAP-IT (USB), before direct Sanger 176	  
sequencing of both strands using BigDye Terminator v.3.1 chemistry v.3.1 (Applied 177	  
Biosystems) and an ABI 3730XL Genetic Analyzer (Applied Biosystems). 178	  
Sequencing traces were analyzed with Sequencher software v.4.2 (Gene Codes). 179	  
 180	  
RESULTS 181	  
1. Clinical description of the patients 182	  
The affected Chihuahua dogs were a 1-year 10 month old male neutered and a 2-year 183	  
1 month old female at the time of presentation. The male started to demonstrate 184	  
clinical signs at 1 year 4 months of age and the female at one year of age. They both 185	  
demonstrated progressive vision deficits, pacing and behavioral changes. On 186	  
examination, the dogs appeared disorientated, poorly responsive and were bumping 187	  
into objects. They were ataxic on all limbs and had a wide-based stance. The female 188	  
dog also demonstrated an intermittent right head tilt. Proprioceptive positioning was 189	  
normal and there were mildly delayed hopping responses in all limbs. Segmental 190	  
spinal reflexes were normal. Menace responses were absent bilaterally with intact 191	  
dazzle reflexes and normal pupillary light reflexes. Remaining cranial nerves 192	  
examination, segmental spinal reflexes and vertebral column palpation were within 193	  
normal limits. No significant abnormalities were detected on physical examination, 194	  
including eye fundus examination. A complete blood count and biochemistry were 195	  
mainly unremarkable, with the exception of a moderate increase in liver enzymes and 196	  
bile acid stimulation tests in the male dog (Alanine aminotransferase: 372 IU/L – 197	  
reference interval (RI) <90; aspartate aminotransferase: 55 IU/L – RI<40; pre-198	  
prandial bile acids: 5.3 µmol/L – RI<5 and post prandial bile acids: 50 µmol/L – 199	  
RI<15). MRI in both cases demonstrated a severe dilatation of the entire ventricular 200	  
system of the brain. The interthalamic adhesion appeared markedly decreased in size; 201	  
the cerebellar sulci and the fissures between the cerebellar folia were noticeably 202	  
widened. These changes suggested marked brain atrophy (Fig. 2A). Cerebrospinal 203	  
fluid (CSF) analysis was unremarkable. Urine organic acids were measured by mass 204	  
spectrometry in the male dog and were not suggestive of a disorder of organic acid 205	  
metabolism.  206	  
In light of the MRI changes, breed and in the absence of CSF abnormalities, a storage 207	  
disease, and more specifically NCL, was highly suspected. The dogs were discharged 208	  
with no treatment and the owners were warned of the very poor prognosis. Due to the 209	  
deterioration of the clinical signs, both owners elected for euthanasia of their dogs 210	  
within a month of discharge, but only the owners of the male dog agreed to post-211	  
mortem examination.	  212	  
  	  213	  
2. Histopathological features	  214	  
On gross examination of the brain, a moderate and symmetrical dilation of the lateral 215	  
ventricles was noted, associated with a thin cortex. Histopathological examination 216	  
demonstrated widespread amorphous to globular, eosinophilic to golden-brown, 217	  
intracytoplasmic storage material within neurons and astrocytes within the cerebral 218	  
cortex, basal ganglia, hippocampus, thalamus, brainstem and cerebellum (Fig. 2 and 219	  
3). All storage material within astrocytes and neurons stained variably magenta with 220	  
Periodic Acid-Schiff (PAS), variably positive with Sudan blue and intensively 221	  
positive with Luxol fast blue (Fig. 2C and D). When viewed under a microscope 222	  
equipped for epifluorescence illumination, as previously described (Katz et al., 223	  
2005b), inclusion material fluoresced brightly (Fig. 2E). In the cortical grey matter 224	  
neuronal necrosis was absent but neuronal density was reduced and remnant laminar 225	  
neurons were disarrayed, and associated with an increased number of reactive 226	  
astrocytes and activated microglia.  Within the cerebellum, Purkinje cells contained 227	  
abundant intracytoplasmic storage material. There was some disorganization and a 228	  
subjectively moderate decrease in the number of Purkinje cells, and several of the 229	  
remaining Purkinje cells showed a mildly shrunken with hypereosinophilic cytoplasm 230	  
and pyknotic nuclei (degeneration). Granular layer neurons were markedly reduced in 231	  
density (Fig. 3). Neurons within the pyramidal layer of the hippocampus contained 232	  
abundant intracytoplasmic storage but were present in normal numbers. 233	  
Immunohistochemical staining confirmed the marked neuroinflammation with a high 234	  
number of GFAP-positive astrocytes (Fig. 2G). Moreover, the tissue showed strong 235	  
staining against LAMP-1 (lysosomal-associated membrane protein 1), indicative of 236	  
alterations in this protein of the lysosome membrane (Fig. 2F).  Finally, ganglion cells 237	  
within the retina were markedly reduced in number and when present contained 238	  
abundant intracytoplasmic storage material (Fig. 2I). Storage material was also found 239	  
in the duodenum, liver and heart using PAS staining and immunohistochemistry 240	  
against LAMP-1.	  241	  
Based on these characteristics, NCL was diagnosed. NCL is a heterogeneous group of 242	  
diseases, and further characterization involves ultrastructural analysis of the storage 243	  
material. EM showed a complex multilamellar profile with presence of curvilinear 244	  
and rectilinear profiles (Fig. 2H).  245	  
	  246	  
3. Molecular analysis	  247	  
Non synonymous mutations in the following previously known NCL genes were 248	  
identified: ARSG (p.Val262Asp, CLN6 (p.Lys29Arg), TPP1 (rs22973585) and 249	  
MFSD8 (p.Phe282Leufs13*). ARSG, CLN6 and TPP1 variants did not segregate with 250	  
the disease phenotype and were therefore excluded as the causative mutations. The 251	  
MFSD8 single pair deletion segregated within the available members of the family, 252	  
with affected dogs being homozygous for the mutation, both clinically unaffected 253	  
parents heterozygous for the mutation and clinically unaffected relatives either 254	  
heterozygous for the mutation or homozygous for the wild-type allele (Fig. 4). This 255	  
mutation is predicted to result in a severely truncated protein, which further supports 256	  
this to be the causal mutation. 	  257	  
	  258	  
DISCUSSION	  259	  
In this study, we describe a family of dogs diagnosed with a mutation in MFSD8 260	  
(CLN7) resulting in neuronal ceroid lipofuscinosis. The mutation is predicted to 261	  
induce a frame shift leading to a premature stop codon.  262	  
The two littermates were monitored for clinical signs of degenerative brain disease, 263	  
mainly for the development of blindness, ataxia and cognitive impairment. These 264	  
changes, secondary to marked brain atrophy, are very similar to those observed in 265	  
patients affected with NCL or other animal forms of the disease. Presence of typical 266	  
autofluorescent cytoplasmic inclusions associated with marked neuronal loss and 267	  
astrocytosis confirmed the diagnosis of NCL. Numerous sporadic reports of 268	  
Chihuahua dogs affected with NCL have been described in the literature with a total 269	  
number of six previously described cases (Rac and Giesecke, 1975; Kuwamura et al., 270	  
2003; Nakamoto et al., 2011). Similarities in age of onset, clinical signs and nature of 271	  
the inclusion make it likely that these animals were affected by the same mutation as 272	  
the dogs presented here. The previous descriptions concerned Chihuahua dogs from 273	  
Japan and Australia, which suggests a world-wide distribution of the mutation. It may 274	  
also be possible that the disease is not recognized by veterinarians, or that it is 275	  
confused with other diseases such as hydrocephalus that is relatively common in the 276	  
breed and can present with similar clinical signs. A commercial diagnostic test should 277	  
be considered in order to determine the frequency of the mutations and to eradicate it 278	  
from the breed.  279	  
Interestingly, the same mutation has recently been strongly suspected as the cause of 280	  
NCL in a single dog of another breed, the Chinese Crested, although lack of family 281	  
ancestry did not allow further confirmation by segregation analysis (Guo et al., 2015). 282	  
Our report is a further confirmation of this previously identified mutation. The clinical 283	  
signs, age of onset, imaging and pathologic findings were very similar to that 284	  
described here. The prevalence of the mutation in the Chinese crested population was 285	  
extremely low (only one heterozygous animal out of 1478 tested Chinese crested), 286	  
which makes it unlikely that a carrier animal could be found to start a colony to use as 287	  
animal model. The presence of the identical mutation in the two breeds would suggest 288	  
a common ancestor for the affected Chinese crested and Chihuahua dogs, possibly 289	  
through another dog breed from Mexico, the Mexican hairless dog (Xoloitzcuintle). 290	  
The Mexican hairless dogs and Chinese crested dogs are hairless dog breeds, which 291	  
are very likely to be related as they carry an identical mutation at the origin of their 292	  
alopecia (Drogemuller et al., 2008).   293	  
 294	  
To identify the mutation, we sequenced the whole genome of one of the affected dogs 295	  
and compared it with the canine reference genome sequence. This allowed us to scan 296	  
initially for sequence variants in the coding and splicing regions of the canine 297	  
orthologs of the previously known genes to cause NCL in human patients. This 298	  
approach has been previously reported by others and was successful at finding 299	  
mutations causing NCL in dogs (Guo et al., 2014; Gilliam et al., 2015; Guo et al., 300	  
2015). One of the genes (ARSG) considered as a candidate gene for NCL has now 301	  
been re-classified as causative of a form of mucopolysaccharidosis (MPS IIIE) 302	  
(Kowalewski et al., 2012; Kowalewski et al., 2015). However, the close proximity of 303	  
these neurodegenerative disorders made exclusion of a mutation in this gene 304	  
important.  305	  
 306	  
In human patients, mutations in the CLN7/MFSD8 gene generally result in a late-307	  
infantile form, now called CLN7 disease. Symptoms are usually first noted between 308	  
the age of 2 to 7 years with seizures and developmental regression. Progression of the 309	  
disease results in motor and mental impairment, and blindness, leading to premature 310	  
death occurring before adulthood in most patients (Kousi et al., 2012). Despite being a 311	  
significant cause of late-infantile NCL in people (Aiello et al., 2009), very little is 312	  
known about the pathophysiology of CLN7, which is in part due to (until recently) the 313	  
lack of suitable animal models (Damme et al., 2014). MFSD8 is a lysosomal 314	  
membrane protein belonging to the major facilitator superfamily (MFS). It is thought 315	  
to act as a transporter but its substrate is still currently unknown (Damme et al., 2014). 316	  
A mouse model of Mfsd8 disruption has been created and should contribute to a better 317	  
understanding of this form of NCL, especially regarding the function of the protein 318	  
and the disease mechanisms. Unfortunately, this model has limitations, as it does not 319	  
accurately reproduce the clinical and histopathological findings seen in human 320	  
patients (Damme et al., 2014). No obvious neuronal loss is observed in these mice, 321	  
although marked accumulation of autofluorescent material in the nerve cells and 322	  
retinal degeneration (photoreceptor layer) is evident. The failure to reproduce all key-323	  
features of the human disease may be due to the presence of residual Cln7 protein 324	  
function in these mice. In contrast, the Chihuahua dogs presented here could represent 325	  
a better model as the histopathologic findings mimic the human pathology with 326	  
marked neuronal loss and astrocytosis, resulting in progression of neurological signs 327	  
incompatible with life (Table III). In the dog presented here, the Purkinje cells layer 328	  
appears relatively spared - although signs of degeneration are visible – compared to 329	  
what is observed in human patients. This difference could be due to the fact that the 330	  
dog has been euthanized at a reasonably early stage of the disease. Indeed, this layer 331	  
tends to be progressively lost in patients contrary to the granular cells layer, which is 332	  
completely lost at very early age (Elleder et al., 2011). Overall, canine models are a 333	  
good complement to murine models, especially for assessment of potential therapies 334	  
due to a closer phenotype and longer lifespan (Faller et al., 2015). Additionally, the 335	  
Chihuahua breed would be a particularly promising model due to its reasonably small 336	  
size and ease of handling, which would make them particularly suitable as research 337	  
individuals. However, further histological characterization of dogs of both sexes and 338	  
of different ages would be needed for a better understanding of the progression of the 339	  
disease.  340	  
 341	  
In conclusion, we have identified a mutation in MFSD8 causing Neuronal Ceroid 342	  
Lipofuscinosis in Chihuahua dogs. This breed could represent a good animal model of 343	  
CLN7 disease.  344	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FIGURE LEGENDS  500	  
 501	  
Figure 1: Pedigree of the family of Chihuahua dogs. Solid figures represent affected 502	  
dogs, whereas plain figures are clinically unaffected dogs. Squares represent males 503	  
and circles females. Genotypes of the tested dogs are mentioned under each figure 504	  
with WT = wild-type allele and Del = MFSD8:c.843delT:p.Phe282Leufs13* allele.  505	  
 506	  
Figure 2: Magnetic resonance imaging and histological findings of the male dog. A: 507	  
Sagittal T2-weighted image of the brain. Note the marked generalised cerebral 508	  
atrophy. B: H&E staining of the cerebellum at high magnification showing inclusions 509	  
within the Purkinje cells (arrows). C & D: Periodic acid-Schiff (C) and Luxol Fast 510	  
Blue (D) staining of brainstem neurons at high magnification. E:Fluorescence cryostat 511	  
section of the cerebral cortex showing abundant autofluorescent inclusions. F & G: 512	  
Lysosomal staining by use of anti-LAMP-1 antibody of the cerebellum of the affected 513	  
dog (F) and of a control dog (G). H: Immunostaining against GFAP (brainstem). I: 514	  
Electron microscopy of the storage bodies from the cerebral cortex. Note the mixed 515	  
nature of the inclusions with curvilinear (*) and rectilinear (arrow) profiles. J. H&E 516	  
staining of a retinal section. Note the marked depletion of the ganglion cells.  517	  
NFL: nerve fiber layer. GCL: ganglion cell layer. IPL: inner plexiform layer. INL: 518	  
inner nuclear layer. OPL: outer plexiform layer. ONL: outer nuclear layer. RL: 519	  
receptor layer.   520	  
 521	  
Figure 3: H&E sections of the vermis of the cerebellum of the affected dog (A1 and 522	  
A2) and of a control dog (B1 and B2) at low and high magnification. Note the marked 523	  
depletion in granule cells in the affected dog (the blue line in each panel spans the 524	  
granular layer). This results in an overall marked atrophy of the cerebellar cortex. In 525	  
the affected dog, there is a moderate decrease in number of Purkinje cells (*), which 526	  
show signs of degeneration. NB: in the control dog, at high magnification (B2), the 527	  
white lamina is not seen due to the normal thickness of the granule cell layer, 528	  
preventing visualisation of the white lamina in the same image as the three layers of 529	  
cerebellar grey matter.  530	  
 531	  
Figure 4: Sequence traces showing a small portion of the genomic DNA of the 532	  
Chihuahua dogs shown in the pedigree (Fig. 2), and centered around the mutation of 533	  
interest (MFSD8:c.843delT:p.Phe282Leufs13*). All sequences are aligned against the 534	  
canine reference genome (CanFam3.1).  535	  
 536	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Table	  I.	  Table	  of	  Primary	  Antibodies	  Used.	  	  547	   	  548	  
Antigen	   Description	  of	  Immunogen	  
Source,	  Host	  Species,	  
Cat.	  #,	  Clone	  or	  Lot#,	  
RRID	  
Concentration	  Used	  
LAMP-­‐1	   Lysosomal	  associated	  membrane	  protein	  1	   Abcam,	  mouse	  monoclonal,	  Cat#	  ab25630	  RRID	  :	  AB_470708	   1:200	  	  	  Glial	  fibrillary	  acidic	  protein	  (GFAP)	   GFAP	  isolated	  from	  bovine	  spinal	  cord	   Dako,	  Rabbit	  monoclonal,	  Cat#	  Z0334,	  RRID:AB_2314535	   1:1000	  	  549	  550	  
Table II: Homozygous variants in the coding region or splicing areas of previously 551	  
known NCL genes used for Sanger sequencing confirmation and segregation 552	  
analyses.  553	  
Gene 
(transcript) 
Variant 
location Primers 
ARSG 
(XM_005624176.1) 
p.Val262Asp 
 
F: 5’-ACCTCTTGGCTTTCCCATTG-3’ 
R: 5’-CAGGGAGCTAGCTGGGTTTT-3’ 
CLN6 
(NM_001011888.1) 
p.Lys29Arg F: 5’-CACAGTGCTTCCCGCAAC-3’ 
R: 5’-CACCAAAACCGCATCCTACT-3’ 
TPP1 
(NM_001013847.1)	  
Splice site 
(rs22973585) 
F: 5’-GCTCACAGTGTGCACATGTG-3’ 
R: 5’-GAGTACCTGATGAGTGCCGG-3’ 
CLN7/ MFSD8 
(XM_533294.4) 
c.843delT; 
p.F282Lfs13* 
F: 5’-ATCTCCTGGGAAGAAAATTCAC-3’ 
R: 5’-TTAAATCATGGCACTGAAGTTTT-3’ 
 554	  
Only the mutation identified in MFSD8:c.843delT:p.Phe282Leufs13* segregated with 555	  
the disease in the studied family. 556	   	  557	   	  558	  559	  
Table III: Comparison of the phenotypes of human CLN7 disease, the Mfsd8(tm1a/tm1a) 560	  
mouse model (Damme et al., 2014) and the canine model described here and in the 561	  
literature.  562	  
Neuropathological 
features 
CLN7 disease 
(humans) 
Mfsd8(tm1a/tm1a) (mice)  
(Damme et al 2014) 
CLN7 disease 
(canine) 
Retinal degeneration Yes Yes Yes (this report, 
Kuwamura et al., 
2003) 
Accumulation of 
SCMAS (Sub-unit C 
of mitochondrial ATP 
synthase) 
Yes Yes Not performed 
Accumulation of 
autofluorescent ceroid 
lipopigments 
Yes Yes Yes (this report; 
Kuwamura et al., 
2003; Guo et al., 
2015) 
Astrogliosis Yes Only mildly Yes (this report, Guo 
et al., 2015; 
Kuwamura et al., 
2003; Nakamoto et al., 
2011) 
Generalised seizures Yes No No (this report; Guo et 
al., 2015; Kuwamura 
et al., 2003) 
Suspected partial 
seizure (jaw 
chomping) (Rac et al., 
1975) 
Terminal stage 
(Nakamoto et al., 
2011) 
Myoclonus/ataxia Yes Yes Yes (ataxia) (this 
report; Guo et al., 
2015; Rac et al., 1975; 
Nakamoto et al., 
2011) 
Neuronal loss / brain 
atrophy 
Yes No Yes (this report, Guo 
et al., 2015; Rac et al., 
1975; Nakamoto et al., 
2011; Kuwamura et 
al., 2003) 
Premature death Yes (mean age 11.5 
years) (Kousi et al 
No Yes (euthanasia as not 
compatible with life) – 
2009) ~ 1.5 - 2 years (lifespan 
of a Chihuahua or a 
Chinese Crested dog > 
12 years) (this report; 
Kuwamura et al., 2003; 
Rac et al., 1975; 
Nakamoto et al., 2011; 
Guo et al., 2015). 
Table adapted from Damme et al. (2014) 563	  
